AMRS - Amyris, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3500
0.0000 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.3500
Open4.3600
Bid4.01 x 2200
Ask4.50 x 4000
Day's Range4.2600 - 4.4773
52 Week Range3.1900 - 9.2900
Volume615,782
Avg. Volume1,355,731
Market Cap331.311M
Beta (3Y Monthly)-1.30
PE Ratio (TTM)N/A
EPS (TTM)-3.03
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Trade prices are not sourced from all markets
  • Company behind Chanel perfume gets into sweetener business
    Yahoo Finance Video10 days ago

    Company behind Chanel perfume gets into sweetener business

    The Bay area company Amyris unveils a zero calorie naturally sourced sweetener in an attempt to carve out health issues for consumers. Yahoo Finance’s Alexis Christoforous speaks to Amyris CEO John Melo.

  • GlobeNewswireyesterday

    Amyris Receives GRAS Notification from FDA for its New, Sugarcane-Derived, Zero Calorie Sweetener

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, announced today that it has received a successful GRAS notification from the US Food and Drug Administration (FDA) for its zero calorie sweetener. With this notification, the FDA has accepted the unanimous conclusion of a panel of food-safety experts, we announced on August 30, 2018, that Amyris’s zero calorie sweetener made from sugarcane is safe for use as a sweetener. The sweetener has the highest level of purity available today, the best taste of any alternative sweetener, and is made from a sustainable production process using fermentation.

  • GlobeNewswire2 days ago

    Amyris Closes on Debt Solution

    Amyris, Inc. (AMRS) (the “Company”), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has successfully closed on the previously-announced sale of $60 million of unsecured convertible senior notes (the "Notes"), in a private placement with two “accredited investors” (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933). “We are very pleased with the support of our investors in addressing and simplifying our debt while we continue to deliver significant product sales growth across our business and pursue a truly exciting opportunity for us to disrupt the sweetener market with a healthier alternative,” said John Melo, Amyris President and CEO.

  • Health Care Digest: Where were the women in Gilead's CEO search — and more
    American City Business Journals3 days ago

    Health Care Digest: Where were the women in Gilead's CEO search — and more

    Gilead's CEO search, Amyris' cannabis consideration and Principia's opportunity in this week's Health Care Digest.

  • GlobeNewswire3 days ago

    Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand

    EMERYVILLE, Calif. and LEÓN, Spain, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), a leader in the development and production of pure, sustainable, fermentation-derived ingredients for Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has executed an expanded agreement for its existing production contract with ADL Bionatur Solutions (MAB:ADL), through its fermentation division ADL Biopharma. ADL Bionatur, a European leader in research and development of health products, services and industrial fermentation production, provides cost effective, contract manufacturing capabilities.

  • GlobeNewswire6 days ago

    Amyris Takes Major Step Forward in Addressing its Convertible Debt

    Amyris, Inc. (AMRS) (the “Company”), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has entered into definitive agreements for the sale of $60 million of unsecured convertible senior notes (the "Notes"), in a private placement with two “accredited investors” (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933). The initial conversion price for the Notes will be $6.32, a 52% premium to the closing price of Amyris common stock on December 6, 2018. The buyers may elect to convert the Notes at the conversion price at any time following the issuance date and the Company will have the option to cash settle a conversion undertaken by the buyers.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of AMRS earnings conference call or presentation 13-Nov-18 9:30pm GMT

    Q3 2018 Amyris Inc Earnings Call

  • GlobeNewswire9 days ago

    Amyris Celebrates Launch of New Zero Calorie, Naturally-Derived Sweetener

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, announced the accelerated commercialization of its new zero calorie, sugarcane-derived sweetener in 2019 in partnership with several food and beverage industry leaders. Amyris and its partners are ushering in the next wave in better-for-you, better-for-the planet sweeteners. While many other sweeteners on the market today are made with impurities that may result in a bitter aftertaste, Amyris’s sweetener is made from sugarcane using a proprietary process of fermentation to create the product at scale, yielding a sweetener with 95 percent purity – far higher than competitors.

  • Once a cleantech darling, this East Bay company looks to pour it on with syn-bio sweetener
    American City Business Journals10 days ago

    Once a cleantech darling, this East Bay company looks to pour it on with syn-bio sweetener

    The company pivoted from drugs to biofuels to health and beauty products. Now it rolling out its first entry in the $90 billion sugars and sweeteners market.

  • U.S. and China set to finalize a trade deal in the next three months
    Yahoo Finance10 days ago

    U.S. and China set to finalize a trade deal in the next three months

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.

  • GlobeNewswire10 days ago

    Amyris Partners with Camil Alimentos to Deliver Zero Calorie Sweetener Made from Sugarcane to Brazilian Consumers

    Amyris, Inc. (AMRS), a leader in the research, development and production of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, has announced today a new partnership with Camil Alimentos (B3:CAML3), one of the largest food companies in Latin America to meet growing consumer demand for zero calorie natural sweeteners. The agreement, which provides exclusivity between Camil Alimentos and Amyris in Latin America, consists of the development of an innovative option of a natural sweetener, zero calorie and extracted from sugarcane. The partnership which will begin in Brazil, a country in which the company leads the sugar category and offers the most complete portfolio of the segment, will be the first market to receive the innovation.

  • GlobeNewswire13 days ago

    Amyris Partners with Givaudan to Introduce a Tabletop Application for its Zero Calorie, Naturally Sourced Sweetener

    Amyris, Inc. (AMRS), a leader in the research, development and production of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, recently announced the launch of a new, sugarcane-derived, zero calorie sweetener. Today, Amyris announces the introduction of a new tabletop sweetener application developed in collaboration with Givaudan, a flavor industry leader in the science behind sugar and taste. To address this, Amyris has developed a sweetener that is naturally sourced from sugarcane, has zero calories and has the best taste profile of any sweetener on the market.

  • Here's Why Amyris Can't Stop Sliding This Week
    Motley Fool27 days ago

    Here's Why Amyris Can't Stop Sliding This Week

    The company published SEC filings that go into more detail than its recent press release -- and investors don't like what they see.

  • Here's Why Amyris Is Getting Obliterated Today
    Motley Fool29 days ago

    Here's Why Amyris Is Getting Obliterated Today

    The synthetic biology pioneer reported third-quarter 2018 operating results.

  • GlobeNewswirelast month

    Amyris Reports Third Quarter 2018 Financial Results

    Q3 2018 GAAP revenue of $14.9 million, compared with GAAP revenue of $24.2 million for Q3 2017. Third-quarter revenue of $14.9 million compared with the same period in 2017 of.

  • Benzingalast month

    Amyris Q3 Earnings Outlook

    Amyris, Inc. (NASDAQ: AMRS ) announces its next round of earnings this Tuesday, Nov. 13. Here's Benzinga's advanced look at Amyris' Q3 earnings report. Earnings and Revenue Based on Amyris management projections, ...

  • Simply Wall St.last month

    Amyris Inc (NASDAQ:AMRS): Is Breakeven Near?

    Amyris Inc’s (NASDAQ:AMRS): Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The US$472m market-cap posted a loss in its most recent financial year of -US$93m and Read More...

  • GlobeNewswirelast month

    Amyris Further Expands Relationship with Yifan Pharmaceutical Co., Ltd.

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has already expanded its original collaboration with Yifan Pharmaceutical Co., Ltd. (SZ.002019) (“Yifan”) from its September 2018 agreement. Yifan will add a second molecule from Amyris to its vitamin portfolio. This new multi-million-dollar collaboration between Amyris and Yifan deepens the partnership between the two companies, with immediate revenue from developing products and expected product commercialization as early as 2021, as well as plans for additional products in the future.

  • Amyris (AMRS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zackslast month

    Amyris (AMRS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Amyris (AMRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswirelast month

    Amyris to Announce Third Quarter 2018 Financial Results on Tuesday, November 13, 2018

    EMERYVILLE, Calif., Oct. 30, 2018 -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the third quarter ended September 30, 2018 after market close on Tuesday,.

  • GlobeNewswire2 months ago

    Amyris Partners with IPCA Labs to Earn the 2018 CPhI Award for Excellence in Pharma: API Development

    EMERYVILLE, Calif. and MADRID, Spain, Oct. 23, 2018 -- At the prestigious CPhI Pharma Awards Gala held October 9, in Madrid, Ipca Laboratories, Ltd. was awarded the 2018 CPhI.

  • GlobeNewswire2 months ago

    Amyris Successfully Producing its New Zero Calorie Natural Sweetener at Industrial Scale

    Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, is pleased to announce that industrial scale production of what it believes is the world’s best tasting and lowest cost zero calorie natural sweetener has started and is successfully operating as expected. Amyris recently signed its first major supply and distribution agreement for its sweetener with ASR Group, the world’s largest cane sugar refiner and expects other agreements to follow very soon. “Our team has done an incredible job successfully scaling our technology to produce what we believe to be the world’s leading natural sweetener,” said Amyris President & CEO John Melo.

  • Better Synthetic Biology Stock: Amyris vs. Codexis
    Motley Fool2 months ago

    Better Synthetic Biology Stock: Amyris vs. Codexis

    Both stocks have gained over 140% in the last year alone. Both are looking forward to growth from innovative sweetener ingredients. One doesn't belong in your portfolio.

  • GlobeNewswire2 months ago

    Amyris Signs First Major Supply and Distribution Agreement for its New, Zero Calorie Sweetener with ASR Group, the World’s Largest Cane Sugar Refiner

    Amyris, Inc. (AMRS) a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets today announced it has signed its first major supply and distribution agreement for its new, sugarcane-derived, zero calorie sweetener with ASR Group, the world’s largest cane sugar refiner. “We are pleased to collaborate with Amyris to deliver a great-tasting, zero calorie sweetener made from cane sugar to the marketplace.  This product is among the highest in purity and best in flavor profile that we have seen,” said Richard Dyer, Chief Science and Innovation Officer for ASR Group.